Genomic analysis in lymphoid leukemias

Reviews in Clinical and Experimental Hematology

Volumn 9, Issue 1, 2005, Pages

  Chiaretti, Sabina ^a   Ritz, Jerome ^b,c   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CELL LINEAGE; CHRONIC LYMPHATIC LEUKEMIA; DATA ANALYSIS; DNA MICROARRAY; DNA PROBE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMICS; HUMAN; LYMPHATIC LEUKEMIA; MULTIPLE MYELOMA; PREDICTION; PROGNOSIS; SERIAL ANALYSIS OF GENE EXPRESSION;

EID: 23944484699     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (140)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 339: 605-615, 1998
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Me 350: 1535-1548, 2004
3. Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 162-192, 2002
4. Faderl S, Kantarjian HM, Talpaz M, et al. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91: 3995-4019, 1998
5. Thandla S, Aplan PD. Molecular biology of acute lymphocytic leukemia. Semin Onco 24: 45-56, 1997
6. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36: 263-273, 2000
7. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342: 998-1006, 2000
8. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 88: 4252-4258, 1996
9. Foa R, Vitale A, Mancini M, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol 120: 484-487, 2003
10. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 87: 1211-1224, 1996
11. Silverman LB, Gelber RD, Dalton VK. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97: 1211-1218, 2001
12. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 14: 2234-2239, 2000
13. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 290: 2001-2007, 2003
14. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95: 3310-3322, 2000
15. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14: 2223-2233, 2000
16. Gokbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 6: 114-141, 2002
17. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 27: 540-559, 2000
18. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18: 547-561, 2000
19. Linker C, Damon L, Ries C, et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 20: 2464-2471, 2002
20. Bernard O, Guglielmi P, Jonveaux P, et al. Two distinct mechanisms for the SCL gene activation in the t(1;14) translocation of T-cell leukemias. Genes Chromosomes Cancer 1: 194-208, 1990
21. Bash RO, Hall S, Timmons CF, et al. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study. Blood 86: 666-676, 1995
22. Mellentin JD, Smith SD, Cleary ML. Lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 58: 77-83, 1989
23. Boehm T, Baer R, Lavenir I, et al. The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C delta locus on human chromosome 14q11 and a transcribed region of chromosome 11p15. Embo J 7: 385-394, 1988
24. Boehm T, Foroni L, Kaneko Y, et al. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 88: 4367-4371, 1991
25. Bernard OA, Busson-LeConiat M, Ballerini P, et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 15: 1495-1504, 2001
26. Dube ID, Kamel-Reid S, Yuan CC, et al. A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood 78: 2996-3003, 1991
27. Schiffer CA, Larson RA, Bloomfield CD. Cancer and Leukemia Group B (CALGB) studies in adult acute lymhocytic leukemia. Leukemia 6 (Suppl. 2): 171-174, 1992
28. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337: 61-66, 1991
29. Catovsky D, Foa R. The lymphoid leukemias. In: Butterwords ed. London; 1990
30. Montserrat E, Gomis F, Vallespi T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 78: 1545-1551, 1991
31. Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 102: 1035-1041, 2003
32. Mauro FR, Gentile M, Mancini F, et al. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone. Haematologica 87: 602-608, 2002
33. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-1854, 1999
34. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847, 1999
35. Maloum K, Davi F, Merle-Beral H, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 96: 377-379, 2000
36. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100: 1177-1184, 2002
37. De Rossi G. Prognosis in chronic lymphocytic leukemia (CLL): experience of the Italian cooperative group (GIMEMA). Bone Marrow Transplant 4 (Suppl. 1): 162-164, 1989
38. Dhodapkar M, Tefferi A, Su J, et al. Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study. Leukemia 7: 1232-1235, 1993
39. Molica S, Brugiatelli M, Callea V, et al. Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol 52: 216-221, 1994
40. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 94: 448-454, 1999
41. Barlogie B, Shaughnessy J, Munshi N, et al. Plasma cells myeloma. In: Williams Hematology 6th ed. McGraw-Hill, New York 1279-1304, 2001
42. Ho PJ, Joshua D. The biology and cytogenetics of multiple myeloma. Rev Clin Exp Hem 6: 276-300, 2002
43. Shaughnessy JD Jr, Barlogie B. Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling. Immunol Rev 194: 140-163, 2003
44. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 13: 609-630, 1958
45. Polliack A. Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disordes. Rev Clin Exp Hem 6: 366-382, 2002
46. Tallman MS. Current treatment strategies for patients with hairy cell leukemia. Rev Clin Exp Hem 6: 389-397, 2002
47. Loughran TP. Clonal diseases of large granular lymphocytes. Blood 82: 1-14, 1993
48. Oshimi K, Yamada O, Kaneko t, et al. Laboratory findings and clinical courses of 33 patients with granular lymphocytes-proliferative disorders. Leukemia 7: 782-788, 1993
49. Gentile TC, Uner AH, Hutchison RE, et al. CD3+ CD56+ aggressive variant of large granular lymphocyte leukemia. Blood 84: 2315-2321, 1994
50. Pandolfi F, Loughran TP Jr, Starkebaum G, et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer 65: 341-348, 1990
51. Poisez BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc Natl Acad Sci USA 77: 7415-7419, 1980
52. Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-1 provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 89: 948-956, 1997
53. Catovsky D, Greaves MF, Rose M, et al. Adult T-cell lymphoma in black from the West Indies. Lancet i: 639-643, 1982
54. Pombo de Oliveira MPS, Matutes E, Schulz TF, et al. T-cell malingnancies in Brazil. Clinico-pathological and molecular studies of HTLV-1 positive and negative cases. Int J Cancer 60: 823-827, 1995
55. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukaemia: clinical and hematologic features of 16 cases. Blood 50: 481-492, 1977
56. Okamoto T, Ohno Y, Tsugane S et al. Multi-step carcinogenesis model for adult T cell leukemia. Jpn J Cancer Res 80: 191-195, 1989
57. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257: 967-971, 1992
58. Velculescu VE, Zhang L, Vogelstein B, et al. Serial analysis of gene expression. Science 270: 484-487, 1995
59. Diatchenko L, Lau YF, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 93: 6025-6030, 1996
60. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470, 1995
61. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14: 1675-1680, 1996
62. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998
63. Tavazoie S, Hughes JD, Campbell MJ, et al. Systematic determination of genetic network architecture. Nat Genet 22: 281-285, 1999
64. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442, 2002
65. Slonim DK. From patterns to pathways: gene expression data analysis comes of age. Nat Genet 32 (Suppl.): 502-508, 2002
66. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999
67. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133-143, 2002
68. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102: 2951-2959, 2003
69. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 103: 1043-1049, 2004
70. Moos PJ, Raetz EA, Carlson MA, et al. Identification of gene expression profiles that segregate patients with childhood leukemia. Clin Cancer Res 8: 3118-3130, 2002
71. Staal FJ, van der Burg M, Wessels LF, et al. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 17: 1324-1332, 2003
72. Kohlmann A, Schoch C, Schnittger S, et al. Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer 37: 396-405, 2003
73. Kohlmann A, Schoch C, Schnittger S, et al. Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia 18: 63-71, 2004
74. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30: 41-47, 2002
75. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 243: 59-75, 2000
76. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75-87, 2002
77. Ferrando AA, Neuberg DS, Dodge RK, et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 363: 535-536, 2004
78. Ballerini P, Blaise A, Busson-Le Coniat M, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 100: 991-997, 2002
79. Cave H, Suciu S, Preudhomme C, et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 103: 442-450, 2004
80. Chiaretti S, Li X, Gentleman R, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 103: 2771-2778, 2004
81. Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 105: 821-826, 2005
82. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20: 5695-5707, 2001
83. Biondi A, Cimino G, Pieters R, et al. Biological and therapeutic aspects of infant leukemia. Blood 96: 24-33, 2000
84. Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 81: 2386-2393,1993
85. Felix CA, Lange BJ, Hosler MR, et al. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res 55: 4287-4292, 1995
86. Felix CA, Hosler MR, Winick NJ, et al. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85: 3250-3256, 1995
87. Debernardi S, Lillington DM, Chaplin T, et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 37: 149-158, 2003
88. Ferrando AA, Armstrong SA, Neuberg DS, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 102: 262-268, 2003
89. Armstrong SA, Golub TR, Korsmeyer SJ. MLL- rearranged leukemias: Insights from gene expression profiling. Semin Hemat 40: 268-273, 2003
90. Tsutsumi S, Taketani T, Nishimura K, et al. Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res 63: 4882-4887, 2003
91. Gilliland DG, Griffin JD. The roles of FLT-3 in hematopoiesis and leukemia. Blood 100: 1532-1542, 2002
92. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT-3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326-4335, 2002
93. Taketani T, Taki T, Sugita K, et al. FLT-3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103: 1085-1088, 2004
94. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT-3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100: 59-66, 2002
95. Armstrong SA, Mabon ME, Silverman LB, et al. FLT-3 mutations in childhood acute lymphoblastic leukemia. Blood 103: 3544-3546, 2004
96. Brown P, Levis M, Shurtleff S, et al. FLT-3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT-3 expression. Blood 105: 812-820, 2005
97. Stone RM, De Angelo J, Galinsky I, et al. PKC 412 FLT-3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol 83 (Suppl. 1): S89-90, 2004
98. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT-3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3: 173-183, 2003
99. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351: 533-542, 2004
100. Cheok MH, Yang W, Pui CH, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34: 85-90, 2003
101. Willenbrock H, Juncker AS, Schmiegelow K, et al. Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays. Leukemia 18: 1270-1277, 2004
102. Teuffel O, Dettling M, Cario G, et al. Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia. Haematologica 89: 801-808, 2004
103. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194: 1639-1647, 2001
104. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194: 1625-1638, 2001
105. Chan AC, Iwashima M, Turck CW, et al. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 71: 649-662, 1992
106. Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol 12: 242-249, 2000
107. Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol 9: 205-212, 1997
108. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101: 4944-4951, 2003
109. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99: 2262-2264, 2002
110. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 363: 105-111, 2004
111. Durig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17: 2426-2434, 2003
112. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348: 1764-1775, 2003
113. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351: 893-901, 2004
114. Durig J, Nuckel H, Huttmann A, et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 101: 2748-2755, 2003
115. Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 22: 3937-3949, 2004
116. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997
117. Lane DP. Cancer. p53, guardian of the genome. Nature 358: 15-16, 1992
118. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413-5417, 1991
119. Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 91: 4342-4349, 1998
120. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580-1589, 1995
121. Stankovic T, Hubank M, Cronin D, et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 103: 291-300, 2004
122. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104: 1428-1434, 2004
123. Underhill GH, George D, Bremer EG, Kansas GS, et al. Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood 101: 4013-4021, 2003
124. Tarte K, Zhan F, De Vos J, et al. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 102: 592-600, 2003
125. Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 100: 2175-2186, 2002
126. De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 21: 6848-6857, 2002
127. De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98: 771-780, 2001
128. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745-1757, 2002
129. Zhan F, Tian E, Bumm K, et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101: 1128-1140, 2003
130. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102: 4504-4511, 2003
131. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101: 4998-5006, 2003
132. Dring AM, Davies FE, Fenton JA, et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 10: 5692-5701, 2004
133. Munshi NC, Hideshima T, Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103: 1799-1806, 2004
134. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 101: 3849-3856, 2003
135. Harousseau JL, Shaughnessy J Jr, Richardson P. Multiple myeloma. In: Hematology (ASH, San Diego, CA, December 4-7, 2004) 237-256, 2004
136. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 199: 59-68, 2004
137. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukemia by immunocytochemical detection of Annexin A1 (ANXA1). Lancet 363: 1869-1870, 2004
138. Daibata M, Matsuo Y, Machida H, Taguchi T, et al. Differential gene-expression profiling in the leukemia cell lines derived from indolent and aggressive phases of CD56+ T-cell large granular lymphocyte leukemia. Int J Cancer 108: 845-851, 2004
139. Choi YL, Makishima H, Ohashi J, et al. DNA microarray analysis of natural killer cell-type lymphoproliferative disease of granular lymphocytes with purified CD3-CD56+ fractions. Leukemia 18: 556-565, 2004
140. Tsukasaki K, Tanosaki S, De Vos S, et al. Identifying progression-associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays. Int J Cancer 109: 875-881, 2004